Curis to Release Second Quarter 2008 Financial Results and Hold Conference Call on...

* Reuters is not responsible for the content in this press release.

Wed Jul 23, 2008 9:15am EDT 

Curis to Release Second Quarter 2008 Financial Results and Hold Conference Call on July 30, 2008

CAMBRIDGE, Mass.--(Business Wire)--
Curis, Inc. (NASDAQ:CRIS), a drug development company focused on
developing proprietary targeted medicines primarily for cancer
treatment, today announced that the Company will release its second
quarter financial results on Wednesday, July 30, 2008 before the
market opens. The Company will also hold a conference call on the same
day at 9:00 A.M. Eastern time to discuss: (i) its Hedgehog antagonist
program under collaboration with Genentech, (ii) CUDC-101 and other
proprietary targeted cancer programs, (iii) its financial results as
of and for the three- and six-month periods ended June 30, 2008, and
(iv) additional corporate activities. Daniel Passeri, President and
Chief Executive Officer of Curis, will host the call.

   To access the live conference call, please call (866) 356-4123
from the United States or Canada or (617) 597-5393 from other
locations, shortly before 9:00 A.M. EDT. The conference ID number is
42440244. The conference call can also be accessed on the Curis
website at www.curis.com in the Investors section. Replay will be
available approximately two hours after the completion of the call and
through 5:00 P.M. EDT, Wednesday, August 13, 2008. To access the
replay, please call (888) 286-8010 from the United States or Canada or
(617) 801-6888 from other locations and reference the conference ID
number 84085781.

   About Curis, Inc.

   Curis is a drug development company that is committed to
leveraging its innovative signaling pathway drug technologies to seek
to create new medicines, primarily for cancer. In expanding its drug
development efforts in the field of cancer through its targeted cancer
drug development platform, Curis is building upon its previous
experiences in targeting signaling pathways for the development of
next generation targeted cancer therapies. For more information, visit
Curis' website at www.curis.com.

Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.